> ## Content Index
> Fetch the complete content index at: https://www.coios.me/llms.txt
> Use this file to discover other available public pages before exploring further.

# Type 2 diabetes remission is uncommon, brief and usually ended by a treatment restart
- URL: https://www.coios.me/type-2-diabetes-remission-is-uncommon-brief-and-usually/
- Published: 2026-10-18T11:24:23.000Z
- Updated: 2026-10-18T12:15:58.000Z
- Description: Recorded remission reached 3.82% at five years in treated adults, and ended more often by treatment restart than rising HbA1c.
- Author: Daniel Ryan
- Tags: Health today, Obesity, diabetes and GLP-1, What linked data reveals, United States, #preprint, #new, #item, #source-2026-10, #score-68

The study estimated how often type 2 diabetes remission is recorded in routine care and how long it lasts. It used 136,781 adults with laboratory-confirmed type 2 diabetes in linked electronic health record and claims data. Remission needed two HbA1c values below 6.5%, 90-365 days apart, at least 3 months after stopping all glucose-lowering drugs. Five-year cumulative incidence was 3.82% in 96,817 previously treated adults and 13.27% in 39,964 untreated at entry. Median first remission lasted 226 days; within five years 47.83% ended with treatment restart and 31.94% with glycaemic relapse. Remission and its end were defined from recorded HbA1c and prescribing, so restarts may reflect prescribing practice.

*Why it is interesting: Remission recorded in routine care is rare and brief. The commonest end point is a prescription restart rather than a rise in HbA1c.*

Source

[medRxiv, 16 October 2026](https://doi.org/10.64898/2026.10.14.26365480?ref=coios.me)

Paper

Remission of Type 2 Diabetes in Linked Health Records: Uncommon, Short-Lived, and More Often Ended by Treatment Restart Than by Rising HbA1c

Authors

Lobelo F, Durieux J, Kim DS, Colovos C

DOI

10.64898/2026.10.14.26365480

Type

Preprint

Design

Retrospective cohort in linked EHR-claims data; 136,781 adults with laboratory-confirmed type 2 diabetes (96,817 previously treated, 39,964 untreated at entry), Aalen-Johansen competing-risk follow-up to 5 years

Verdict

New finding

Driver

[Obesity, diabetes and GLP-1](https://www.coios.me/d-obesity-diabetes/)

Driver

[What linked data reveals](https://www.coios.me/d-linked-data/)